Pipeline Portfolio

We SCOHIA PHARMA have several development programs, aiming to establish an innovative product pipeline portfolio focused on metabolic, cardiovascular and renal diseases.
The compound code beginning with SCO- is given to compounds that were decided to perform GLP tox studies.